Skip to content

Identification and Validation of Sepsis-Associated Acute Kidney Injury Biomarkers Based on Multi-Omics Analysis

Identification and Validation of Sepsis-Associated Acute Kidney Injury Biomarkers Based on Multi-Omics Analysis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500104580
Enrollment
Unknown
Registered
2025-06-19
Start date
2025-07-01
Completion date
Unknown
Last updated
2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis-Associated Acute Kidney Injury

Interventions

Sepsis group:None
Sepsis-Associated Acute Kidney Injury (SA-AKI) group:None
Other types of acute kidney injury group:None

Sponsors

The First Affiliated Hospital of Harbin Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Age> = 18 years; 2. Sepsis patients who meet the criteria of sepsis-3; 3. Patients with sepsis are diagnosed with SA-AKI when serum creatinine increases by 0.3 mg/dl (>26.5 umol/L) over 48 hours, or increases to more than 1.5 times the baseline value, or urine output decreases to no more than 0.5 mL/kg/hour for at least 6 hours, according to the Kidney Disease Improvement Overall Outcome (KDIGO) guidelines.

Exclusion criteria

Exclusion criteria: 1. Discharged or died within 48 hours of admission; 2. Chronic kidney disease (CKD) or other known kidney disease; 3. Receiving renal replacement therapy (such as hemodialysis, peritoneal dialysis) before admission; 4. Kidney transplantation or nephrectomy; 5. Serious diseases, such as malignant tumors, autoimmune diseases, acquired immunodeficiency diseases; 6. Pregnant or lactating women; 7. Insufficient clinical information.

Design outcomes

Primary

MeasureTime frame
3-Methylhistidine;Inosine;Creatine;3- hydroxybutyric acid;Arginine;Neutrophil Gelatinase-Associated Lipocalin;Kidney Injury Molecule-1;AKI diagnosis time;Recovery time of renal function;The duration of CRRT treatment;7-day mortality rate;28-day mortality rate;Hospitalization mortality;Sequential Organ Failure Assessment Score;Acute Physiology and Chronic Health Evaluation II Score;Duration of Mechanical Ventilation;Creatinine;Blood Urea Nitrogen;Urinary Output;Fatty acid-binding protein;

Secondary

MeasureTime frame
Length of stay in ICU;Total Hospitalization Duration;Blood Lactate;Interleukin-6;Procalcitonin;C-Reactive Protein;D-dimer;Albumin;Site of Infection;

Countries

China

Contacts

Public ContactWang Changsong

The First Affiliated Hospital of Harbin Medical University

changsongwangicu@163.com+86 137 9661 3356

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026